Literature DB >> 9673885

CA-125 concentrations in the serum and pregnancy outcome in IVF cycles.

A W Brandenberger1, N A Bersinger, P R Huber, E Berger, P Glanzmann, M H Birkhaeuser.   

Abstract

PURPOSE: CA-125 has been proposed as a potential marker for endometrial receptivity in assisted reproduction. This study was designed to evaluate whether the levels of CA-125 in the serum of patients undergoing IVF-embryo transfer (ET) is correlated with the outcome.
METHODS: Levels of serum CA-125 were measured on the day before and on the day of human chorionic gonadotropin (hCG) administration, ovum pickup (OPU), and ET in 74 patients undergoing 100 IVF cycles between January 1994 and March 1995. Patients were treated with a midluteal-phase gonadotropin-releasing hormone (GnRH) agonist protocol and follicular-phase human menopausal gonadotropin.
RESULTS: One hundred oocyte retrievals resulted in 91 ETs, and 22 clinical pregnancies (22%/OPU and 24.2%/ET). The live-born rate was 21%/OPU and 23.1%/ET. Neither the CA-125 serum levels nor their increase from the day of hCG until the day of ET showed any prognostic significance to the outcome of IVF, and they were not correlated with the endometrium thickness or the number of oocytes retrieved or fertilized.
CONCLUSIONS: The CA-125 serum levels in conventional IVF cycles were not correlated with the IVF outcome and yielded no prognostic information in a GnRH agonist down-regulation protocol.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9673885      PMCID: PMC3455013          DOI: 10.1023/a:1022589101648

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  13 in total

1.  Elevated levels of CA-125 in serum of patients suffering from ovarian hyperstimulation syndrome.

Authors:  W Jäger; K Diedrich; L Wildt
Journal:  Fertil Steril       Date:  1987-10       Impact factor: 7.329

Review 2.  The role of tumor markers in gynecologic oncology.

Authors:  G Olt; A Berchuck; R C Bast
Journal:  Obstet Gynecol Surv       Date:  1990-09       Impact factor: 2.347

3.  Correlation of serum and follicular fluid concentrations of placental protein 14 and CA-125 in in vitro fertilization-embryo transfer patients.

Authors:  A Chryssikopoulos; T Mantzavinos; N Kanakas; E Karagouni; E Dotsika; P A Zourlas
Journal:  Fertil Steril       Date:  1996-10       Impact factor: 7.329

4.  Follicular fluid alpha-fetoprotein, carcinoembryonic antigen, and CA-125 levels in relation to in vitro fertilization and gonadotropin and steroid hormone concentrations.

Authors:  P Jimena; J A Castilla; J P Ramirez; T Gil; M Acebal; R Molina; A J Herruzo
Journal:  Fertil Steril       Date:  1993-06       Impact factor: 7.329

5.  CA-125 is present in significant concentrations in periovulatory follicles of in vitro fertilization patients.

Authors:  N Mordel; S O Anteby; G Zajicek; I Roisman; A Treves; V Barak
Journal:  Fertil Steril       Date:  1992-02       Impact factor: 7.329

6.  Tumour-associated antigens, CEA, CA 125 and SCC in serum and follicular fluid of stimulated and unstimulated cycles.

Authors:  I Phocas; A Sarandakou; D Rizos; F Dimitriadou; T Mantzavinos; P A Zourlas
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1994-04       Impact factor: 2.435

7.  Reactivity of a monoclonal antibody with human ovarian carcinoma.

Authors:  R C Bast; M Feeney; H Lazarus; L M Nadler; R B Colvin; R C Knapp
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

8.  Relationship between serum CA 125 levels, endometrial thickness and corpus luteum function in different stages of ovarian activity.

Authors:  G Ozakşit; N O Turhan; H Oral; N Doğu; O Gökmen
Journal:  J Endocrinol Invest       Date:  1993-03       Impact factor: 4.256

9.  Cancer antigen 125 is produced by human endometrial stromal cells.

Authors:  P Bischof; L Tseng; P A Brioschi; W L Herrmann
Journal:  Hum Reprod       Date:  1986-11       Impact factor: 6.918

10.  Are pregnancy-associated plasma protein-A (PAPP-A) and CA 125 measurements after IVF-ET possible predictors of early pregnancy wastage?

Authors:  P Bischof; T M Mignot; L Cédard
Journal:  Hum Reprod       Date:  1989-10       Impact factor: 6.918

View more
  1 in total

1.  Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands.

Authors:  Wei He; Sumith A Kularatne; Kimberly R Kalli; Franklyn G Prendergast; Robert J Amato; George G Klee; Lynn C Hartmann; Philip S Low
Journal:  Int J Cancer       Date:  2008-10-15       Impact factor: 7.396

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.